Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions

Hao, Yan; Zhu, Yajuan; Zou, Song; Zhou, Pei; Hu, Yawen; Zhao, Qixiang; Gu, Linna; Zhang, Haozhou; Wang, Zhen; Li, Jiong

doi:10.3389/fimmu.2021.711060

Cited by 75 publications

(99 citation statements)

References 139 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inflammation in psoriasis is perpetuated by many factors, namely dysregulated native and adaptive immune response, increased oxidative stress, altered balance of adipokines, insulin resistance, and endothelial dysfunction [ 17 , 20 , 21 ]. Insulin resistance is commonly present in patients with psoriasis and contributes to the progression of psoriatic disease.…”

Section: Mechanistic Associations Between Psoriasis and Cardiometabol...mentioning

confidence: 99%

“…Furthermore, inflammation-induced insulin resistance increases endothelial expression of adhesion molecules, which promotes further inflammation in psoriatic plaques [ 23 ]. Proinflammatory cytokines, whose production is markedly increased in psoriasis (TNF-α, IL-17, IL-23, and IL-6) all contribute significantly to insulin resistance in patients with psoriasis [ 21 , 24 ].…”

Section: Mechanistic Associations Between Psoriasis and Cardiometabol...mentioning

confidence: 99%

See 1 more Smart Citation

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

Šabović

Zorko

Janić

2022

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic systemic inflammatory disease. Due to systemic inflammation, it is associated with many comorbidities. Among them, cardiovascular diseases represent the most common causes of morbidity and mortality in this population. Therefore, physicians treating patients with psoriasis should keep in mind that, as important as the treatment of psoriasis, awareness of cardiovascular risk deserves additional attention. Thus, in parallel with psoriasis treatment, a cardiovascular risk assessment must also be performed and addressed accordingly. In addition to encouraging non-pharmacologic strategies for a healthy lifestyle, physicians should be familiar with different pharmacologic options that can target psoriasis and reduce cardiovascular risk. In the present article, we present the pathophysiological mechanisms of the psoriasis and cardiometabolic interplay, our view on the interaction of psoriasis and cardiovascular disease, review the atherosclerotic effect of therapeutic options used in psoriasis, and vice versa, i.e., what the effect of medications used in the prevention of atherosclerosis could be on psoriasis.

show abstract

Section: Mechanistic Associations Between Psoriasis and Cardiometabol...mentioning

confidence: 99%

Section: Mechanistic Associations Between Psoriasis and Cardiometabol...mentioning

confidence: 99%

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

Šabović

Zorko

Janić

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…This may be compounded by the increased risk of metabolic syndrome in psoriasis with considerable immunological overlap and systemic inflammation seen in both disorders [39]. Metabolic syndrome is associated with increased risk of major adverse cardiac events and the risk of metabolic syndrome is higher in patients who are heavy drinkers > 35 g/day (RR 1.86) [39,40]. Psoriasis patients are also at increased risk of AF with an HR of 1.42 compared with controls [41].…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene

Kearney

Kirby

2022

Am J Clin Dermatol

View full text Add to dashboard Cite

Psoriasis patients are at increased risk of harmful alcohol use and alcohol dependency with many deleterious effects. Increasing alcohol use is associated with worsening psoriasis severity, is a risk factor for poor response to systemic treatments and may impact on comorbidities such as psoriatic arthritis, cardiovascular disease, cancer and liver disease. Harmful alcohol use and alcohol dependency can be defined by the updated ICD-11 coding system and screening can be completed using many tools including the Cut down, Annoyed, Guilty, Eye-Opener (CAGE), Alcohol Use Disorders Identification Test (AUDIT) and Michigan Alcohol Screening Test (MAST) questionnaires. Dermatologists may be able to complete brief interventions encouraging alcohol reduction in psoriasis patients. Psoriasis patients may respond to messages of gain with reduced psoriasis severity and loss with reduced cardiovascular risk. It is important for dermatologists to discuss alcohol with all psoriasis patients, to be aware of the impact of alcohol in psoriasis and to familiarise themselves with screening tools, brief intervention and local services available to patients who require specialist input for harmful alcohol use or alcohol dependency.

show abstract

“… 1 , 2 Although certain progress has been made in the treatment of psoriasis, this disease still cannot be completely cured and often leads to many complications, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome, uveitis, etc. 3 , 4 , 5 , 6 In addition to these complications, the body appearance of the psoriasis patient is also affected 7 , 8 ; all of these factors contribute to a huge psychological burden (such as anxiety and depression) on the psoriasis patients, which causes difficulties in rehabilitation and even leads to suicide. 9 , 10 , 11 Therefore, it is necessary to explore potential factors that participate in the pathology of anxiety and depression, which might be helpful for attribution therapy and thereby improve the clinical outcomes of psoriasis patients.…”

Section: Introductionmentioning

confidence: 99%

The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients

Tong

Yang

Dai

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objective Proinflammatory cytokines mediate anxiety and depression in various ways, such as immunity, inflammation, and the hypothalamic–pituitary–adrenal axis. This study intended to further explore the linkage of common proinflammatory cytokine levels with anxiety and depression in psoriasis patients. Methods Totally, 150 psoriasis patients and 50 healthy controls (HCs) were included; the serum samples were collected, then common proinflammatory cytokines were measured by ELISA. Hospital Anxiety and Depression Scale (HADS) was assessed. Results HADS‐anxiety (HADS‐A) score, HADS‐depression (HADS‐D) score, TNF‐α, IL‐1β, IL‐6, IL‐12, IL‐17A, and IL‐23 were all increased in psoriasis patients compared to HCs (all p < 0.05). In psoriasis patients, TNF‐α ( p = 0.001), IL‐12 ( p = 0.035), and IL‐17A ( p < 0.001), but not IL‐1β ( p = 0.255), IL‐6 ( p = 0.248), and IL‐23 ( p = 0.216), were positively linked to HADS‐A score. Meanwhile, TNF‐α ( p = 0.007) and IL‐17A ( p = 0.007) were enhanced in psoriasis patients with anxiety in contrast to those without anxiety; whereas IL‐1β ( p = 0.178), IL‐6 ( p = 0.360), IL‐12 ( p = 0.239), and IL‐23 ( p = 0.450) were not different. TNF‐α ( p < 0.001), IL‐1β ( p = 0.013), Il‐17A ( p < 0.001), and IL‐23 ( p = 0.023), but not IL‐6 ( p = 0.143) and IL‐12 ( p = 0.158), were positively linked to HADS‐D score. Concurrently, TNF‐α ( p = 0.015), IL‐17A ( p < 0.001), and IL‐23 ( p = 0.017) were climbed in psoriasis patients with depression by comparison to those without depression; whereas IL‐1β ( p = 0.113), IL‐6 ( p = 0.237), IL‐12 ( p = 0.660) did not differ. Conclusion TNF‐α, IL‐17A, and IL‐23 increments reflect anabatic anxiety and depression in psoriasis patients, uncovering the potency of proinflammatory cytokines measurement for monitoring or even preventing psoriasis patients' anxiety and depression.

show abstract

Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions

Cited by 75 publications

References 139 publications

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

Killing Two Birds with One Stone: Potential Therapies Targeting Psoriasis and Atherosclerosis at the Same Time

Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene

The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients

Contact Info

Product

Resources

About